Prevalence of Anti-PF4/Heparin Antibodies and the HIT Syndrome in Cardiovascular Medicine

Heparin-induced thrombocytopenia (HIT) is a potentially life-threatening adverse effect of heparin treatment. HIT is mediated by antibodies directed at complexes that form between heparin and platelet factor 4 in plasma and are located on the platelet surface and on endothelium. HIT occurs in 1 to 2% of patients receiving unfractionated heparin (UFH) and with lower frequency in patients receiving low-molecular-weight heparins and heparinoids. Despite recent insights into the mechanisms of HIT, there remain important unresolved issues. For example, the reason for the wide difference in the frequency of HIT in patients treated with UFH in various clinical trials is not yet clear. There are patient population-dependent differences in the risk for HIT immunoglobulin G and the development of thrombotic episodes. The complex nature of this syndrome may relate to the composition of the responsible antigen. Patients with HIT need a more accurate evaluation of platelet counts and a better assessment of clinical evidence for thrombosis. Alternative anticoagulant therapy approaches are being studied, but there is at this time no firm clinical evidence for which treatment is best for patients with HIT and HIT-related thromboses.

KEYWORDS

Heparin-induced thrombocytopenia - HIT - pathophysiology - low-molecular-weight heparin - LMWH - cardiac surgery - anticoagulation

REFERENCES

• 1 Warkentin T E, Chong B H, Greinnacher A. Heparin induced thrombocytopenia. Toward consensus.  Thromb Haemost. 1998;  79 1-7
• 2 Fabris F, Ahmad S, Cella G, Jeske W P, Walenga J M, Fareed J. Pathophysiology of heparin-induced thrombocytopenia. Clinical and diagnostic implications-review.  Arch Pathol Lab Med. 2000;  124 1657-1666
• 3 Warkentin T E, Sheppard J I, Horsewood P, Simpson P J, Moore J C, Kelton J G. Impact of the patient population on the risk for heparin-induced thrombocytopenia.  Blood. 2000;  96 1703-1708
• 4 Chong B H, Grace C S, Rozenberg M C. Heparin-induced thrombocytopenia: effect of heparin platelet antibody on platelets.  Br J Haematol. 1981;  49 531-540
• 5 Amiral J, Bridey F, Wolf M et al.. Antibodies to macromolecular platelet factor-4-heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases.  Thromb Haemost. 1995;  73 21-28
• 6 Newman P M, Chong B H. Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation.  Blood. 2000;  96 182-187
• 7 Horne K M, Hutchinson K J. Simultaneous binding of heparin and platelet factor-4 to platelets: further insights into mechanism of heparin-induced thrombocytopenia.  Am J Hematol. 1998;  58 24-30
• 8 Warkentin T E, Kelton J G. Delayed-onset heparin-induced thrombocytopenia and thrombosis.  Ann Intern Med. 2001;  135 502-506
• 9 Lee D H, Warkentin T E, Denomme G A, Hayward C P, Kelton J G. A diagnostic test for heparin-induced thrombocytopenia: detection of platelet microparticles using flow cytometry.  Br J Haematol. 1996;  95 724-731
• 10 Sheridan D, Carter C, Kelton J G. A diagnostic test for heparin-induced thrombocytopenia.  Blood. 1986;  67 27-30
• 11 Greinacher A, Amiral J, Dummel V, Kiefel V, Mueller-Eckhardt C. Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay.  Transfusion. 1994;  34 381-385
• 12 Amiral J, Fareed J. Thromboembolic diseases: biochemical mechanisms and new possibilities of biological diagnosis.  Semin Thromb Hemost. 1996;  22 41-48
• 13 Warkentin T E, Kelton J G. A 14-year study of heparin-induced thrombocytopenia.  Am J Med. 1996;  101 505-527
• 14 Warkentin T. Heparin induced thrombocytopenia; a ten-year retrospective.  Annu Rev Med. 1999;  50 129-147
• 15 Warkentin T E, Kelton J G. Interaction of heparin with platelets including heparin-induced thrombocytopenia. In: Bounameaux H Low Molecular Weight Heparins in Prophylaxis and Therapy of Thromboembolic Diseases: Fundamental and Clinical Cardiology. New York; Marcel Dekker 1994: 75-127
• 16 Warkentin T E, Levine M N, Hirsh J et al.. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.  N Engl J Med. 1995;  332 1330-1335
• 17 Hirsh J, Warkentin T E, Raschke R, Granger C, Ohman E M, Dalen J E. Heparin and low-molecular-weight heparin. Mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy and safety.  Chest. 1998;  114 489S-510S
• 18 Lubenow N, Kempf R, Eichner A, Eichler P, Carlsson L E, Greinacher A. Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin.  Chest. 2002;  122 37-42
• 19 Lee D H, Warkentin T E. Frequency of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A Heparin-Induced Thrombocytopenia. 2nd ed. New York; Marcel Dekker 2001: 87-121
• 20 Francis J L, Palmer III G J, Morose R, Drexler A. Comparison of bovine and porcine heparin in heparin antibody formation after cardiac surgery.  Ann Thorac Surg. 2003;  75 17-22
• 21 Mattioli A V, Bonetti L, Sternieri S, Mattioli G. Heparin-induced thrombocytopenia in patients treated with unfractionated heparin: prevalence of thrombosis in a 1 year follow-up.  Ital Heart J. 2000;  1 39-42
• 22 Warkentin T E, Levine M N, Hirsh J et al.. Formation of heparin-induced thrombocytopenia IgG without thrombocytopenia: analysis of a clinical trial [abstract].  Blood. 1995;  56 537a
• 23 Warkentin T E, Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery.  Ann Thorac Surg. 2003;  76 638-648
• 24 Greinacher A. Heparin-induced thrombocytopenia-pathogenesis and treatment.  Thromb Haemost. 1999;  82 148-156
• 25 Gruel Y, Lang M, Darnige L. Fatal effect of re-exposure to heparin after previous heparin-associated thrombocytopenia and thrombosis.  Lancet. 1990;  336 1077-1078
• 26 Elalamy I, Potevin F, Lecrubier C, Bara L, Marie J, Samama M. A fatal low-molecular weight heparin associated thrombocytopenia after hip surgery: possible usefulness of PF4-heparin ELISA test.  Blood Coagul Fibrinolysis. 1996;  7 665-671
• 27 Andrew M. Development haemostasis: relevance to thromboembolic complications in pediatric patients.  Thromb Haemost. 1995;  74 415-425
• 28 Cella G, Vittadello O, Galucci V, Girolami A. The release of beta thromboglobulin and platelet factor 4 during extracorporeal circulation for open heart surgery.  Eur J Clin Invest. 1981;  11 165-169
• 29 Singer I O, Sefcick A, Tait R C, Lindsay K W, Walker I D. Antithrombin concentrate alone may not prevent venous thromboembolism following neurosurgery.  Br J Haematol. 1998;  103 583-584
• 30 Heck Jr H A, Lutcher C L, Falls D G. Fatal thrombocytopenic coagulopathy after cardiopulmonary bypass: clinicopathologic correlations implicating heparin.  South Med J. 1994;  87 789-793
• 31 Trossaert M, Gaillard A, Commin P L, Amiral J, Vissac A M, Frassinaud E. High incidence of anti-heparin/platelet factor 4 antibodies after cardio-pulmonary bypass surgery.  Br J Haematol. 1998;  101 653-655
• 32 Bauer T L, Arepally G, Konkle B A et al.. Prevalence of heparin associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery.  Circulation. 1997;  95 1242-1246
• 33 Konkle B A, Bauer T L, Arepally G et al.. Heparin-induced thrombocytopenia: bovine versus porcine heparin in cardiopulmonary bypass surgery.  Ann Thorac Surg. 2001;  71 1920-1924
• 34 Warkentin T E, Heddle N M. Laboratory diagnosis of immune heparin-induced thrombocytopenia.  Curr Hematol Rep. 2003;  2 148-157
• 35 Walls J T, Curtis J J, Silver D, Boley T M, Schmaltz R A, Nawarawong W. Heparin-induced thrombocytopenia in open heart surgical patients: sequelae of late recognition.  Ann Thorac Surg. 1992;  53 787-791
• 36 Visentin G P, Malik M I, Cyganiak K A, Aster R H. Patients treated with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin-platelet factor 4 complexes.  J Lab Clin Med. 1996;  128 376-383
• 37 Warkentin T E, Elavathil L J, Hayward C PM, Johnston M A, Russett J I, Kelton J G. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia.  Ann Intern Med. 1997;  127 804-812
• 38 Greinacher A, Lubenow N. Recombinant hirudin in clinical practice: focus on lepirudin.  Circulation. 2001;  103 1479-1484
• 39 Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of two prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range.  Blood. 2000;  96 846-851
• 40 Gillis S, Merin G, Zahger D et al.. Danaparoid for cardiopulmonary bypass in patients with previous heparin-induced thrombocytopenia.  Br J Haematol. 1997;  98 657-659
• 41 Warkentin T E. Management of heparin-induced thrombocytopenia: a critical comparison of lepirudin and argatroban.  Thromb Res. 2003;  110 73-82
• 42 Lewis B E, Wallis D E, Leya F, Hursting M J, Kelton J G. Argatroban-915 Investigators . Argatroban anticoagulation in patients with heparin-induced thrombocytopenia.  Arch Intern Med. 2003;  163 1849-1856